Share on StockTwits

Halozyme Therapeutics (NASDAQ:HALO) will issue its Q114 quarterly earnings data on Monday, May 12th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $13.37 million for the quarter.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $21.80 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was down 42.7% on a year-over-year basis. On average, analysts expect Halozyme Therapeutics to post $-0.45 EPS for the current fiscal year and $-0.15 EPS for the next fiscal year.

Halozyme Therapeutics (NASDAQ:HALO) opened at 7.09 on Friday. Halozyme Therapeutics has a 52 week low of $5.88 and a 52 week high of $18.18. The stock has a 50-day moving average of $9.11 and a 200-day moving average of $13.0. The company’s market cap is $807.6 million.

Several analysts have recently commented on the stock. Analysts at Citigroup Inc. initiated coverage on shares of Halozyme Therapeutics in a research note on Tuesday, April 15th. They set a “buy” rating and a $12.00 price target on the stock. Analysts at BMO Capital Markets reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, April 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $11.25.

Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.